Perspectives on telemedicine to improve stroke treatment

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Stroke is the number three cause of death and the most common cause of adult disability in the United States. Few patients receive the only established effective therapy, intravenous tissue plasminogen activator. Failure to treat may occur due to several reasons, a crucial one being the lack of acute neurologic coverage, particularly in rural settings. In this article we review the difficulties encountered by patients needing immediate care to access stroke specialists. To overcome this delay in patient care, telemedicine technology for acute stroke care is recommended. We track the emergence and evolution of "telestroke" from initial telephone consultation, to point-to-point, hub-and-spoke networks, to web-based site-independent telestroke systems. We detail the emerging evidence for the safety and efficacy of these remote telestroke systems through observational studies (TEMPiS and REACH). Lastly, we discuss areas where telestroke could potentially expand to provide more complete stroke care beyond the acute thrombolysis phase, as well as its potential to improve clinical research and the need for cost-effective research. We conclude that telestroke is currently the most practical solution to any setback faced by stroke specialists with respect to low thrombolytic rates.

Original languageEnglish (US)
Pages (from-to)157-167
Number of pages11
JournalDrugs of Today
Volume47
Issue number2
DOIs
StatePublished - Apr 1 2011

Fingerprint

Telemedicine
Stroke
Therapeutics
Tissue Plasminogen Activator
Research
Telephone
Nervous System
Observational Studies
Cause of Death
Patient Care
Referral and Consultation
Technology
Safety
Costs and Cost Analysis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Perspectives on telemedicine to improve stroke treatment. / Stewart, Shannon Fredrick; Switzer, Jeffrey A.

In: Drugs of Today, Vol. 47, No. 2, 01.04.2011, p. 157-167.

Research output: Contribution to journalReview article

@article{624e4cfeb1694327b2146f717262ca68,
title = "Perspectives on telemedicine to improve stroke treatment",
abstract = "Stroke is the number three cause of death and the most common cause of adult disability in the United States. Few patients receive the only established effective therapy, intravenous tissue plasminogen activator. Failure to treat may occur due to several reasons, a crucial one being the lack of acute neurologic coverage, particularly in rural settings. In this article we review the difficulties encountered by patients needing immediate care to access stroke specialists. To overcome this delay in patient care, telemedicine technology for acute stroke care is recommended. We track the emergence and evolution of {"}telestroke{"} from initial telephone consultation, to point-to-point, hub-and-spoke networks, to web-based site-independent telestroke systems. We detail the emerging evidence for the safety and efficacy of these remote telestroke systems through observational studies (TEMPiS and REACH). Lastly, we discuss areas where telestroke could potentially expand to provide more complete stroke care beyond the acute thrombolysis phase, as well as its potential to improve clinical research and the need for cost-effective research. We conclude that telestroke is currently the most practical solution to any setback faced by stroke specialists with respect to low thrombolytic rates.",
author = "Stewart, {Shannon Fredrick} and Switzer, {Jeffrey A}",
year = "2011",
month = "4",
day = "1",
doi = "10.1358/dot.2011.47.2.1576694",
language = "English (US)",
volume = "47",
pages = "157--167",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "2",

}

TY - JOUR

T1 - Perspectives on telemedicine to improve stroke treatment

AU - Stewart, Shannon Fredrick

AU - Switzer, Jeffrey A

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Stroke is the number three cause of death and the most common cause of adult disability in the United States. Few patients receive the only established effective therapy, intravenous tissue plasminogen activator. Failure to treat may occur due to several reasons, a crucial one being the lack of acute neurologic coverage, particularly in rural settings. In this article we review the difficulties encountered by patients needing immediate care to access stroke specialists. To overcome this delay in patient care, telemedicine technology for acute stroke care is recommended. We track the emergence and evolution of "telestroke" from initial telephone consultation, to point-to-point, hub-and-spoke networks, to web-based site-independent telestroke systems. We detail the emerging evidence for the safety and efficacy of these remote telestroke systems through observational studies (TEMPiS and REACH). Lastly, we discuss areas where telestroke could potentially expand to provide more complete stroke care beyond the acute thrombolysis phase, as well as its potential to improve clinical research and the need for cost-effective research. We conclude that telestroke is currently the most practical solution to any setback faced by stroke specialists with respect to low thrombolytic rates.

AB - Stroke is the number three cause of death and the most common cause of adult disability in the United States. Few patients receive the only established effective therapy, intravenous tissue plasminogen activator. Failure to treat may occur due to several reasons, a crucial one being the lack of acute neurologic coverage, particularly in rural settings. In this article we review the difficulties encountered by patients needing immediate care to access stroke specialists. To overcome this delay in patient care, telemedicine technology for acute stroke care is recommended. We track the emergence and evolution of "telestroke" from initial telephone consultation, to point-to-point, hub-and-spoke networks, to web-based site-independent telestroke systems. We detail the emerging evidence for the safety and efficacy of these remote telestroke systems through observational studies (TEMPiS and REACH). Lastly, we discuss areas where telestroke could potentially expand to provide more complete stroke care beyond the acute thrombolysis phase, as well as its potential to improve clinical research and the need for cost-effective research. We conclude that telestroke is currently the most practical solution to any setback faced by stroke specialists with respect to low thrombolytic rates.

UR - http://www.scopus.com/inward/record.url?scp=79955879213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955879213&partnerID=8YFLogxK

U2 - 10.1358/dot.2011.47.2.1576694

DO - 10.1358/dot.2011.47.2.1576694

M3 - Review article

C2 - 21431103

AN - SCOPUS:79955879213

VL - 47

SP - 157

EP - 167

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 2

ER -